Good afternoon and welcome to the ChemoCentryx Third Quarter 2019 Financial Results Conference Call. [Operator Instructions]
I would now like to turn the call over to Mr. Bill Slattery of Burns McClellan. Mr. Slattery, Please go ahead.
Thank you. Good afternoon, and welcome to the ChemoCentryx third quarter 2019 financial results conference call. Earlier this afternoon the company issued a press release providing an overview of its financial results for the third quarter ended September 30th, 2019. This press release along with a few slides that you may find helpful while you listen to this call are available on the Investor Relations section of the Company's website at www.chemocentryx.com.
Joining me on the call today is Dr. Thomas Schall, President and Chief Executive Officer of ChemoCentryx, who will review the Company's recent business and clinical progress. Following his comments Susan Kanaya, Executive Vice President, Chief Financial and Administrative Officer at ChemoCentryx will provide an overview of the Company's financial highlights for the third quarter 2019, before turning the call back over to Tom for closing remarks.
During today's call, we will be making certain forward-looking statements, which those of you following the slides can see if you look at Slide two. These forward-looking statements are based on current information, assumptions and expectations that are subject to change and involve a number of risks and uncertainties that may cause actual results to differ materially from those contained in the forward-looking statements. These risks are described in the Company's filings made with the Securities and Exchange Commission including the Company's Annual Report on Form 10-K filed on March 11th, 2019.
You are cautioned not to place undue reliance on these forward-looking statements and ChemoCentryx disclaims any obligation to update such statements. In addition, this conference call contains time sensitive information that is accurate only as of the date of this live broadcast November 4th, 2019. ChemoCentryx undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this live conference call.
At this time, it is my pleasure to turn the call over to Tom Schall. Tom?
Thomas J. Schall
Thank you, Bill, and good afternoon everyone listening. Thank you for joining us on our third quarter 2019 conference call. In the third quarter I adopted a new mantra that I then called four, five, six, which of those of you who are following can see on Slide three. That is we at ChemoCentryx set four clinical programs, yielding five data readouts over the -- then next six quarters.
One quarter later, we are on track with this goal. Today, I will concentrate on the first top-line data events for each of our first two drug candidates, the release of results from our pivotal Phase III ADVOCATE trial of avacopan in the treatment of ANCA associated vasculitis in mid to late Q4 that is this quarter. And then, I'll touch upon two studies of CCX140 for focal segmental glomerulosclerosis or FSGS in LUMINA-1 trial, which is expected to
Thomas J. Schall
President, Chief Executive Officer and Chairman of the Board
Susan M. Kanaya
Executive Vice President, Chief Financial and Administrative Officer and Secretary
Dae Gon Ha
We are pleased that you like our content! Sign Up now to access premium content for free, a very limited time offer.
Welcome! Create your account
You are successfully registered!
An activation link has been sent to your mail. Please activate and login.